NCT02115386View on ClinicalTrials.gov

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib

supplied in 150 mg capsules to be taken orally

Trial Locations (1)

125167

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY